Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. OGI
OGI logo

OGI Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
1.170
Open
1.150
VWAP
1.15
Vol
379.44K
Mkt Cap
160.48M
Low
1.130
Amount
435.09K
EV/EBITDA(TTM)
--
Total Shares
140.78M
EV
280.44M
EV/OCF(TTM)
--
P/S(TTM)
0.78
Organigram Global Inc. is focused on producing cannabis for adult recreational consumers, as well as developing international business partnerships. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT, Collective Project, Fetch and DEBUNK. It operates facilities in Moncton, New Brunswick and LacSuperieur, Quebec, with an edibles manufacturing facility in Winnipeg, Manitoba. It operates two additional cannabis processing facilities in Southwestern Ontario: one in Aylmer and the other in London. The facility in Aylmer houses CO2 and Hydrocarbon extraction capabilities, and is optimized for formulation refinement, post-processing of minor cannabinoids, and pre-roll production. The facility in London is optimized for labeling, packaging, and national fulfillment. Its subsidiaries include Organigram Inc. and Motif Labs Ltd.
Show More

Events Timeline

(ET)
2026-05-12
06:10:00
Sees FY26 Adjusted EBITDA Higher than FY25, CapEx Below $10M
select
2026-05-12
06:10:00
Company Reports Q2 Adjusted EBITDA of $870K
select
2026-04-15 (ET)
2026-04-15
12:10:00
Organigram Completes Acquisition of Sanity Group for €107.3M
select
2026-03-23 (ET)
2026-03-23
06:10:00
Organigram Recommends Shareholders Vote FOR Sanity Group Acquisition
select
2026-02-24 (ET)
2026-02-24
06:10:00
Organigram Launches 10 New Products in Australia
select
2026-02-19 (ET)
2026-02-19
06:30:00
Organigram Enters $65.2M Financing Agreement with British American Tobacco
select
2026-02-19
06:20:00
Organigram Enters $65.2 Million Financing Agreement with British American Tobacco
select
2026-02-18 (ET)
2026-02-18
06:20:00
Organigram Acquires Sanity Group for €113.4 Million
select
2026-02-10 (ET)
2026-02-10
06:20:00
Organigram Reports Q1 Adjusted EBITDA of $5.3M
select

News

seekingalpha
9.5
05-12seekingalpha
Organigram Reports Disappointing Q2 Results, Stock Drops 15%
  • Revenue Decline: Organigram reported net revenue of C$59.8 million ($43.6 million) for Q2 FY2026, reflecting a ~9% year-over-year decline primarily due to lower vape and infused pre-roll sales, marking its first topline contraction since Q2 FY2024 and missing the ~8% growth forecasted by analysts.
  • Gross Margin Drop: The company's gross margin fell by 200 basis points to 31% compared to the prior year, driven by changes in product mix and increased product returns, indicating pressure on profitability amid a competitive market environment.
  • Widening Net Loss: Organigram swung to a net loss of C$0.9 million compared to a net income of C$42.5 million in the same period last year, primarily due to weaker fair value gains on derivative liabilities and preferred shares, alongside declining revenue and gross margin, highlighting a deterioration in financial health.
  • Revised Full-Year Outlook: The company updated its full-year net revenue guidance to over C$350 million from more than C$300 million previously, reflecting revised revenue recognition criteria related to the Sanity Group acquisition in April, indicating cautious optimism for future performance.
seekingalpha
9.5
05-12seekingalpha
Organigram Reports Q2 Net Loss Amid Revenue Decline
  • Financial Performance Decline: Organigram reported a net loss of $0.9 million in Q2 2026, a stark contrast to a net income of $42.5 million in Q2 Fiscal 2025, indicating a significant drop in profitability that may undermine investor confidence.
  • Revenue Downtrend: The company posted total revenue of $93.3 million, a 9.2% year-over-year decline, although it exceeded market expectations by $42.82 million, the ongoing revenue decrease could pressure future growth prospects.
  • Adjusted EBITDA Plummets: Adjusted EBITDA fell to $0.9 million, an 82% decrease compared to $4.9 million in Q2 Fiscal 2025, highlighting significant challenges in cost management and profitability.
  • Stable International Revenue: International revenue remained flat at $6.1 million year-over-year, showing resilience in a declining overall revenue context, which may indicate stable market demand despite broader challenges.
Newsfilter
9.5
05-06Newsfilter
Organigram Announces Q2 Fiscal 2026 Earnings Report Date
  • Earnings Report Schedule: Organigram Global Inc. will report its Q2 fiscal 2026 earnings on May 12, 2026, before market open, reflecting the company's commitment to transparency and investor communication.
  • Conference Call Details: The company will host a conference call at 8:00 AM Eastern Time on the same day to discuss the earnings results, ensuring investors receive timely information for informed decision-making.
  • Webcast Access: Investors can register via the provided link to join the conference call, with confirmation emails sent containing dial-in details, enhancing engagement and participation with stakeholders.
  • Company Background: Organigram is Canada's leading cannabis company focused on producing high-quality cannabis products and expanding its market presence in the US and Canada through acquisitions, demonstrating strategic positioning in a rapidly evolving industry.
Newsfilter
8.5
04-30Newsfilter
Cannabis Edibles Market Experiences Rapid Growth
  • Market Size Projections: The global cannabis edibles market is expected to reach approximately $7.1 billion by 2025 and climb to around $16.6 billion by 2030, indicating a strong growth trajectory driven by consumer demand for cleaner, more discreet consumption methods.
  • Successful International Export: Herbal Dispatch has successfully completed its first export of medical cannabis gummies to Australia, generating approximately $350,000 in revenue, marking a significant milestone in the company's international growth strategy and reinforcing its position as a trusted supplier in the global medical cannabis market.
  • Product Diversification Strategy: Herbal Dispatch is actively expanding its gummies and edibles offerings domestically under the Chomp brand, responding to strong consumer demand across both medical and recreational channels, highlighting the company's focus on convenient, dose-controlled formats to drive long-term growth.
  • Emerging Investment Opportunities: With potential U.S. federal reform and the ongoing expansion of medical programs globally, the cannabis edibles market is positioned at the intersection of several powerful trends, likely capturing a larger market share and driving revenue diversification in high-growth categories.
Newsfilter
8.5
04-15Newsfilter
Organigram Completes Acquisition of Sanity Group
  • Acquisition Completed: Organigram successfully acquired Sanity Group for €107.3 million, comprising €78 million in cash and €29.3 million in shares, marking a significant step in its European market expansion strategy.
  • Financing Arrangement: The acquisition was accompanied by a private placement financing with BAT, raising €40.3 million (approximately C$65.2 million), which provided essential funding support for the acquisition and enhanced the company's financial flexibility.
  • Future Earnings Potential: The acquisition agreement includes earnout provisions of up to €113.8 million based on Sanity Group's financial performance over the next 12 months, reflecting Organigram's confidence in its long-term growth potential.
  • New Board Member: Following the acquisition, Max Konrad Narr was appointed to Organigram's board of directors, expected to provide crucial support for the company's strategic decision-making and market integration.
Newsfilter
8.5
03-31Newsfilter
Organigram Shareholders Approve Acquisition of Sanity Group
  • Shareholder Resolution: At the March 30, 2026, shareholders' meeting, Organigram's shareholders overwhelmingly approved the resolution to acquire Sanity Group with 93% of votes, marking a significant step in the company's global cannabis market expansion.
  • Significant Financial Impact: The acquisition is expected to enhance Organigram's revenue and profitability, with Sanity Group achieving positive EBITDA in 2025, further solidifying Organigram's leadership in the rapidly growing German medical cannabis market.
  • Strategic Integration Benefits: The acquisition will provide Organigram with a vertically integrated European hub, enhancing its commercial, operational, medical, and regulatory expertise across the value chain, facilitating future market expansion.
  • Innovative Product Development: The combination of both teams is expected to drive the development of next-generation cannabis innovations, leveraging science-backed intellectual property to further extend Organigram's brand influence in global markets.
Wall Street analysts forecast OGI stock price to rise
2 Analyst Rating
Wall Street analysts forecast OGI stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
2.36
Averages
2.64
High
2.91
Current: 0.000
sliders
Low
2.36
Averages
2.64
High
2.91
Canaccord
Buy
maintain
$3 -> $4
AI Analysis
2026-02-19
Reason
Canaccord
Price Target
$3 -> $4
AI Analysis
2026-02-19
maintain
Buy
Reason
Canaccord raised the firm's price target on Organigram to C$4 from C$3 and keeps a Buy rating on the shares.
Canaccord
Buy
initiated
$3
2026-01-27
Reason
Canaccord
Price Target
$3
2026-01-27
initiated
Buy
Reason
Canaccord initiated coverage of Organigram with a Buy rating and C$3 price target. The firm says that despite regulatory headwinds and structural inefficiencies, the Canadian cannabis market "remains a global benchmark for legal cannabis commercialization." Organigram is accelerating its transition a vertically integrated global cannabis company, with market leading positions including the number one share in pre-rolls, concentrates and milled flower, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for OGI
Unlock Now

Valuation Metrics

The current forward P/E ratio for Organigram Global Inc (OGI.O) is 46.51, compared to its 5-year average forward P/E of -3.81. For a more detailed relative valuation and DCF analysis to assess Organigram Global Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.81
Current PE
46.51
Overvalued PE
44.83
Undervalued PE
-52.44

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-24.22
Current EV/EBITDA
-2.18
Overvalued EV/EBITDA
221.11
Undervalued EV/EBITDA
-269.56

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
2.25
Current PS
0.36
Overvalued PS
4.38
Undervalued PS
0.12

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

high volitle penny stock tomorrow
Intellectia · 84 candidates
Price: <= $5.00Volume: >= 1,000,000Beta: HighRiskOne Day Rise Prob: >= 0One Day Predict Return: >= 0.0%
Ticker
Name
Market Cap$
top bottom
PGEN logo
PGEN
Precigen Inc
1.48B
ALLO logo
ALLO
Allogene Therapeutics Inc
803.91M
SFIX logo
SFIX
Stitch Fix Inc
426.63M
NOTV logo
NOTV
Inotiv Inc
10.95M
UROY logo
UROY
Uranium Royalty Corp
598.10M
SNBR logo
SNBR
Sleep Number Corp
40.80M
what penny stocks should we attack
Intellectia · 32 candidates
Market Cap: 50.00M - 1.50BRegion: USPrice: $0.50 - $5.00Quarter Revenue Yoy Growth: >= 10.0%Net Margin: >= 0.00List Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 500,000
Ticker
Name
Market Cap$
top bottom
UROY logo
UROY
Uranium Royalty Corp
518.53M
OBIO logo
OBIO
Orchestra Biomed Holdings Inc
249.30M
CGEN logo
CGEN
Compugen Ltd
219.37M
HRZN logo
HRZN
Horizon Technology Finance Corp
212.25M
OVID logo
OVID
Ovid Therapeutics Inc
386.63M
GORO logo
GORO
Gold Resource Corp
194.23M
what stock under $5 should I buy today?
Intellectia · 56 candidates
Market Cap: >= 100.00MRegion: USPrice: $0.50 - $5.00Quarter Revenue Yoy Growth: >= 5.0%List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Monthly Average Dollar Volume: >= 500,000
Ticker
Name
Market Cap$
top bottom
API logo
API
Agora Inc
431.16M
IOVA logo
IOVA
Iovance Biotherapeutics Inc
1.58B
GOGO logo
GOGO
Gogo Inc
599.67M
IMPP logo
IMPP
Imperial Petroleum Inc
188.03M
OCGN logo
OCGN
Ocugen Inc
608.82M
TRON logo
TRON
TRON Inc
359.44M
stocks under 10 expected to gap up today
Intellectia · 26 candidates
Price: $1.00 - $10.00Volume: >= 200,000Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEGap Pattern: GapUpPre Market Price Change: >= $3.00
Ticker
Name
Market Cap$
top bottom
JZXN logo
JZXN
Jiuzi Holdings Inc
1.66M
CDIO logo
CDIO
Cardio Diagnostics Holdings Inc
3.89M
BOXL logo
BOXL
Boxlight Corp
1.24M
TALK logo
TALK
Talkspace Inc
651.03M
ELAB logo
ELAB
PMGC Holdings Inc
1.46M
MOB logo
MOB
Mobilicom Ltd
58.61M
best penny stock to invest in
Intellectia · 28 candidates
Market Cap: 50.00M - 2.00BPrice: $0.50 - $5.00Quarter Revenue Yoy Growth: >= 10.0%Net Margin: >= 0.01List Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 500,000
Ticker
Name
Market Cap$
top bottom
BTCS logo
BTCS
BTCS Inc
74.02M
CPSH logo
CPSH
CPS Technologies Corp
84.14M
NIU logo
NIU
NIU Technologies
262.74M
AKBA logo
AKBA
Akebia Therapeutics Inc
313.13M
OGI logo
OGI
Organigram Global Inc
186.49M
PAYS logo
PAYS
Paysign Inc
179.99M
penny stocks with great upside
Intellectia · 54 candidates
Market Cap: 50.00M - 1.50BPrice: $0.50 - $5.00Quarter Revenue Yoy Growth: >= 20.0%List Exchange: XNYS, XNAS, XASETarget Price Upside Potential: MoreAbovePriceMonthly Average Dollar Volume: >= 500,000
Ticker
Name
Market Cap$
top bottom
TCRX logo
TCRX
TScan Therapeutics Inc
55.18M
XTIA logo
XTIA
XTI Aerospace Inc
56.59M
BWEN logo
BWEN
Broadwind Inc
56.61M
UPXI logo
UPXI
Upexi Inc
56.94M
BTM logo
BTM
Bitcoin Depot Inc
58.90M
AMPG logo
AMPG
Amplitech Group Inc
70.51M
good penny stocks to invest in
Intellectia · 32 candidates
Market Cap: <= 500.00MPrice: <= $5.00Quarter Revenue Yoy Growth: >= 10.0%Beta: HighRiskWeekly Average Turnover: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
CAN logo
CAN
Canaan Inc
498.64M
ORGO logo
ORGO
Organogenesis Holdings Inc
487.34M
CERS logo
CERS
Cerus Corp
485.98M
OCGN logo
OCGN
Ocugen Inc
465.36M
API logo
API
Agora Inc
402.42M
NNDM logo
NNDM
Nano Dimension Ltd
395.43M
Best stock under 3.50 that will 3x
Intellectia · 29 candidates
Market Cap: <= 2.00BPrice: <= $3.50Beta: HighRiskRevenue 5yr Cagr: >= 20Annual Eps Yoy Growth: >= 20.0%
Ticker
Name
Market Cap$
top bottom
CLVT logo
CLVT
Clarivate PLC
1.86B
BITF logo
BITF
Bitfarms Ltd
1.61B
BLND logo
BLND
Blend Labs Inc
732.49M
SNDL logo
SNDL
SNDL Inc
406.85M
LCTX logo
LCTX
Lineage Cell Therapeutics Inc
382.34M
SLQT logo
SLQT
SelectQuote Inc
283.31M

Whales Holding OGI

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Organigram Global Inc (OGI) stock price today?

The current price of OGI is 1.14 USD — it has increased 0

What is Organigram Global Inc (OGI)'s business?

Organigram Global Inc. is focused on producing cannabis for adult recreational consumers, as well as developing international business partnerships. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT, Collective Project, Fetch and DEBUNK. It operates facilities in Moncton, New Brunswick and LacSuperieur, Quebec, with an edibles manufacturing facility in Winnipeg, Manitoba. It operates two additional cannabis processing facilities in Southwestern Ontario: one in Aylmer and the other in London. The facility in Aylmer houses CO2 and Hydrocarbon extraction capabilities, and is optimized for formulation refinement, post-processing of minor cannabinoids, and pre-roll production. The facility in London is optimized for labeling, packaging, and national fulfillment. Its subsidiaries include Organigram Inc. and Motif Labs Ltd.

What is the price predicton of OGI Stock?

Wall Street analysts forecast OGI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OGI is2.64 USD with a low forecast of 2.36 USD and a high forecast of 2.91 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Organigram Global Inc (OGI)'s revenue for the last quarter?

Organigram Global Inc revenue for the last quarter amounts to 59.79M USD, decreased -8.85

What is Organigram Global Inc (OGI)'s earnings per share (EPS) for the last quarter?

Organigram Global Inc. EPS for the last quarter amounts to -0.01 USD, decreased -103.12

How many employees does Organigram Global Inc (OGI). have?

Organigram Global Inc (OGI) has 1139 emplpoyees as of May 31 2026.

What is Organigram Global Inc (OGI) market cap?

Today OGI has the market capitalization of 160.48M USD.